– Specialist HIV company established by GlaxoSmithKline (85%) and Pfizer (15%).
– Corporate members of the Council on Foreign Relations.
– Broad portfolio of 11 marketed products.
– Industry-leading pipeline with 6 innovative potential medicines.
– 19% share of growing worldwide HIV market.
– Strong philanthropic commitment; work with HIV community and activities in developing countries will continue.
– Protease inhibitors: Agenerase, Lexiva/Telzir, Viracept (N. America only).
– Nucleoside reverse transcriptase inhibitors: Combivir, Epivir/3TC, Epzicom/Kivexa, Retrovir/AZT, Trizivir, Ziagen.
– Non-nucleoside reverse transcriptase inhibitors: Rescriptor (US only).
– CCR5 antagonist: Selzentry/Celsentri.
– GSK intends to invest up to £50 million available over 10 years to form the ‘Positive Action for Children fund’. The investment will support NGOs and others working with pregnant mothers to try and prevent mother-to-child-transmission of HIV in the developing world with a particular focus on Sub-Saharan Africa.
– £10 million for a partnership with other private and public sector bodies to address both the R&D and access challenges associated with HIV in Sub-Saharan Africa.
– Voluntary licence agreed, on a non-exclusive basis, with South Africa based Aspen Pharmacare Ltd for the manufacture of Abacavir.
– Shionogi-GlaxoSmithKline Pharmaceuticals LLC, in collaboration with the European AIDS Treatment Group and the Drug Development Committee of the AIDS Treatment Activists Coalition, to revise inclusion criteria for Study ING112276, a dose-ranging study of the investigational integrase inhibitor S/GSK1349572 in antiretroviral therapy-naïve patients.
– FDA approves expanded use of Selzentry (maraviroc) tablets, in combination with other antiretroviral agents, to include adult patients with CCR5-tropic HIV-1 virus who are starting treatment for the first time (treatment-naïve).
– Chief Financial Officer for GSK since April 2005.
– Senior Vice President Operations Controller, member of the pharmaceutical operating committee and chaired the capital review team at GSK (2001-2005).
– Financial Controller of Glaxo Wellcome (1998-2001).
– Senior roles in brewing, property and food businesses and latterly Group Controller at Grand Metropolitan (1986).
– Management accounting and strategic planning roles at Imperial Brewing and Leisure (1979).
– Auditor at Stoy Hayward (1978).
– Chartered accountant working for John M. Winter (1977).
– Board member and CEO.
– Senior Vice President and Head of Personalised Medicine Strategy for GSK since April 2008.
– Member of GSK‘s Positive Action Steering Committee and board member of the GSK France Foundation, which supported a range of HIV/AIDS-related programmes around the world.
– Senior Vice President and Area Director for GSK‘s pharmaceutical business in Southern & Eastern Europe (2003-2008).
– General Manager of GSK France (2000-2003).
– Marketing and Sales Director (1996), General Manager Operations (1999) and Chairman and Managing Director (2000) at Glaxo Wellcome in France.
– Marketing and management positions at Ciba-Geigy (1985-1996).
– Medicomarketing advisor at Negma Laboratory (1983-1985).
– Doctorate in Medicine, a specialisation in occupational medicine, and a Marketing and Management programme earned at Insead.
– Regional President of Europe (which includes Australia/New Zealand on an interim basis) for the Specialty Care Business Unit at Pfizer.
– Regional President of Pfizer Central and Eastern Europe since December 2007 and Country Manager for Italy since May 2008.
– Country Manager of Poland, followed by Country Manager of Belgium/Luxembourg (2000-2004).
– Vice President of Marketing and New Product Development for Pfizer Japan.
– Country Manager of Hungary (1995).
– Assignments in the Marketing and New Product departments, first in the Netherlands and subsequently in New York Headquarters (launch of Norvasc) and in India.
– Medical Department of Pfizer Netherlands (1982).
– Bachelor’s and master’s degrees in Pharmacy from Leiden University in the Netherlands and a licensed pharmacist.
– Senior Vice President and Head of the Infectious Diseases Centre of Excellence for Drug Discovery at GSK since 2007.
– Executive Vice President and Chief Scientific Officer of Ardea Biosciences Inc.
– Vice President and Head of Research at Valeant Pharmaceuticals International.
– Research and management roles at Schering-Plough Research Institute.
– Bachelor’s degree in Biochemistry from Fudan University in Shanghai and Ph.D. in Biochemistry from the State University of New York at Buffalo.
– President Emerging Markets of GSK since June 2009.
– Non-executive director of Aspen Pharmacare Holdings Limited.
– Sales Representative GP & Hospital Sales East London (1988); Associate of Market Research & New Product Planning and subsequently District Sales Manager in Austrlia (1990); Associate of Global Product Planning (Cardiovascular Business Unit) in Indianapolis (1994); Associate of Business Development Asia Pacific (1995); Pharmaceutical Sales & Marketing Director in India (1996); Managing Director of Turkey (1998); General Manager Lilly Deutschland and General Manager and Speaker Lilly Pharma Holding GmbH (2001); European Mid-Size Area Director (2003); Vice President of Europe with specific responsibility for the Western European Mid-Size countries, Africa & Middle East Area/Commonwealth of Independent States and Central & Eastern Europe regions; and President Europe for Eli Lilly and Company.
– Degree in Medicinal Chemistry & Pharmacology from Loughborough University of Technology, UK.
– Senior Vice President, Corporate Communications and Community Partnerships, and member of the Corporate Executive Team of GSK since July 2006.
– Vice President, Global Investor Relations and Competitive Excellence of GSK.
– Joined Glaxo Wellcome in 1991; Investor Relations department (1997); Vice President of Investor Relations (2000); Vice President, Global Investor Relations with responsibility for the global IR function (2001).
– Financial Investigations and Trading Arrangements departments, and Financial Controller of Adechsa S.A., based in Zug, Switzerland.
– Chartered Accountant (1991) at Deloitte and Touche (1988) in London.
– Degree in Chemistry at Durham University.
– President of Pfizer Global Research & Development since 2007.
– Director of Discovery Biology in the UK (1995); Senior Director, Head of Biology (1997); Vice President UK Discovery (1998); Senior Vice President, Head of Worldwide Discovery (1999); Senior Vice President, Head of Worldwide Research and Technology (2003); and Vice President PGRD, Head of Worldwide Development (2007) at Pfizer.
– Advanced Drug Delivery Research Unit and Head of Drug Preformulation and Delivery in Sussex, UK; Head of Molecular and Cell Biology, CNS Research, in Basel, Switzerland (1993-1995) at Ciba-Geigy.
– Postdoctoral research fellowship working on malarial vaccines with Professor John Scaife at the University of Edinburgh and Professor Uli Certa at Hoffman La-Roche Pharmaceuticals in Basel, Switzerland.
– In Antibacterial Discovery at Beecham Pharmaceuticals in Surrey, UK.
– Microbiology First Class Honors Degree at Heriot-Watt University and PhD in Molecular Genetics at the University of Edinburgh.
– Senior Vice President of Strategy, Logistics and External Supply at GSK; joined in 1985, senior production, logistics and continuous improvement roles including Site Director at the Ware manufacturing site in the UK.
– Senior operational roles in both Merck Generics and IVAX.
– Degree in Pharmacy from Heriott Watt University, Edinburgh.
– Senior Vice President and Chief Medical Officer for GSK since August 2008.
– Vice President and Worldwide Therapeutic Area Head for Ophthalmology (2005) and Vice President, Worldwide Business Development at Pfizer.
– Global Vice President of Development for the Ophthalmics Business Unit at Novartis Pharmaceuticals.
– Chief Executive of Virgoen Ltd, a small biotech company in the UK specialising in anti-viral drug discovery and development.
– Senior roles at Bausch & Lomb and Merck & Co.
– Masters Degree in Health Sciences, Epidemiology & Statistics, from the Johns Hopkins Bloomberg School of Public Health as a Carnegie-Mellon Fellow.
– Graduate of Harvard University, Biochemical Sciences and Applied Mathematics, and medical degree from the Johns Hopkins School of Medicine.
– Head of the North America region, responsible for the businesses in the US, Canada and Puerto Rico.
– At GSK: Sales and Marketing positions in the UK and in Global Commercial Development; Area Director for Sub Saharan Africa operations (included marketing and sales responsibility for the HIV product portfolio); Senior VP Sales for US Pharmaceuticals; Office of the CEO coordinating the Support Function Review and supporting launch excellence in GSK Japan.
– BSc Hons in Mathematics and Management Sciences from Manchester University, UK.
– Head Legal Counsel and Company Secretary.
– Member of the North Carolina Bar and the Illinois Bar.
– Assistant General Counsel, Sales, Marketing & Managed Care, US Legal Operations, responsible for providing support to HIV products Epzicom, Combivir and Trizivir, as well as the HIV sales force at GSK.
– BA degrees with Honours in English and Psychology from Bucknell University, Phi Beta Kappa, and Law degree from the University of North Carolina, Chapel Hill.
– Head of Commercial Strategy, including global product strategy for new and marketed products and commercial portfolio management.
– Market Analytics in New Product Development covering HIV and other viral diseases (2001); Worldwide Marketing and leadership role in developing global HIV portfolio, launching Celsentri (marketed in the US as Selzentry) and leading the HIV disease area strategy (2003); HIV prevention strategy at Pfizer.
– Head of Government Affairs, Patient Advocacy, Community Partnership and Access.
– At GSK: Medical & Regulatory Affairs Director Portugal (1984); series of commercial roles of increasing seniority in France, the UK and Portugal; VP and General Manager of pharmaceuticals business in Portugal (1997); significant experience in working with members of the government and local community on market access, healthcare policy and industry reputation issues while running the commercial business including the HIV product portfolio.
– Elected member of the Portuguese Medical Academy and the General Council of Lisbon Public University (Nova).
– Head of Europe, responsible for business.
– At GSK: Field-based roles (1989-1992); product management (1992-1995); Business Unit Head, Neurosciences and Antibiotics in the UK (1995-1997); Director European Market Development (Cardiovascular, Respiratory, and Metabolic & Oncology) and then Group Director and Head of European Market Development (1997-1999); Group Director and Head of the Global Product Strategy Neurosciences and Gastrointestinal team (1999); VP Pharmacogenetics and Diagnostics in R&D; Marketing Director; European Critical Diseases Business Unit (2004-2009) that evolved from an idea into a flourishing European business.
– BTG-funded Post-Doctoral Fellow at the Michigan Cancer Foundation in Detroit.
– BSc and PhD in Pharmacology from the University of Bradford and MBA from the University of Kingston.
– Chief Scientific and Medical Officer, oversees R&D, Regulatory, Safety and Medical Affairs.
– Former Senior Vice president Infectious Diseases Medicine Development Centre for GSK.
– Senior positions at Vertex Pharmaceuticals and Achillion Pharmaceuticals.
– Associate Professor of Internal Medicine in the Section of Infectious Diseases at Rush Medical College in Chicago, and Director of the Outpatient HIV Centre.
– Head of the International region, responsible for the business outside North America and Europe.
– At GSK: Senior roles in sales and marketing positions (1988); General Manager Ukraine (2002); Area General Manager Developing Markets Eurasia (2004-2008), responsible for nine Caucasus and Central Asian markets; VP and General Manager for South Africa business.
– BSc Hons in Biochemistry and Microbiology from Leeds University.
– Head of Human resources.
– Human resources Director for GSK in Australia.
– Human resources director roles in the commercial law firm Clayton Utz, PriceWaterhouseCoopers and BP Australia.
– Bachelor of Business degree in Human resources and Industrial Relations from the Royal Melbourne Institute of Technology.
– Chief Financial Officer, oversees Finance and Business Development.
– Roles within finance (1994); Vice president Corporate Development at GSK.